It might be unfeasible to try and destroy the DPC without surgical means and right now it might not even be possible. But if the DPC is dead due to AGA and the DS is intact, then I dont see why it shouldnt be possible without forced intervention. Perhaps in the distant future this will be commercially viable, its a possibility.
I'm trying to stay ignorantly optimistic. Please dont hit me with a dose a reality.
Quiescent yes, the stem cells do not lose their proliferative capacity or reach their telomerase limit, thanks for correcting me. Its the DPC that become scenescent (study) (study).
My theory is that the frontal DPC's sensitivity to sex steroids has been unintentionally conserved by men when selecting women with thick hairlines, perceiving them to be more youthful and attractive. And this regional difference in DPC response becomes the complete opposite in males, but since women might have given less preference to looks and more on dominance, the genes ended up being conserved.
Even if we did have gene therapy, to me it seems like it would be very difficult to localise it to just the epidermis of the frontal scalp. And the cost might not justify not getting a transplant instead either from healthy regions or cultured DPC if they get that far in the future.
My belief is that the DPC become conditioned during embryogenesis or at some point in the womb and that this is only specific to the DPC. It could very well be that the entire frontal scalp contains the AGA code, but that just seems unintuitive. The stem cells should have the same code regardless of the location (I tell myself). I'm just trying to be optimistic with my delusions.
One thing I find strange is how it takes quite a while for the initial recession to become noticeable but happens quite fast when stopping treatments. I remember reading a study on Hic5/ara55 (Androgen co-activator) and how it starts to get upregulated after puberty. And also reports of Testosterone/DHT being able to upregulate the expression of AR. Perhaps continued activation of AR causes permanent upregulation or enhanced stability of AR. Its also peculiar that RU users stop responding after a while - I mean its not like theres a negative feedback loop here? What do you think?
Looking at CB and RU they seem like the realistic and most ideal AR antagonists currently on the market, they have virtually no systemic effects on the HPTA or GnRH release and only work peripherally. Its just the price and lack of reputable sources (I'm a little cautious of chinese manufacturers) that put me off.

Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis
Also AR is upregulated significantly so that might play a part in increasing the receptor saturation ceiling. It also doesnt make the conclusion robust given that non-AGA DPC have less AR. I want to know what would happen if AR was boosted to AGA levels in non AGA DPC.
We know that DHT/T that causes the binding of β-catenin to AR, and the study showed that without DHT, WNT3a did activate the TCF/LEF genes. Something that worries me is that maybe even an antagonist that binds to AR can recruit β-catenin. I'm thinking if we can prevent the binding of β-catenin to AR, we might not have to worry about Androgens at all. Something that fits into the pocket in place of β-catenin! What about SARMS and steroids? I know there are steroids that have significantly higher AR binding affinities that could easily saturate the receptors, and most of them have altered anabolic:androgenic ratios. Perhaps its the androgenic part that causes this negative response of AGA? Edit: looks like R1881 elicits the same response as T/DHT
Most treatments themselves do not contain the growth factors, they merely stimulate the release indirectly and I'm wondering if all epidermal cells have the ability to release paracrine growth factors. Furthermore, there is only so much you can proliferate the HF shaft with exogenous growth factors, which explains why people only see vellus hairs getting longer. A functioning anagen DPC with an adequate blood supply thickens the diameter of the hair shaft significantly and continually releases growth factors in comparison the infrequent applications of treatments that may or may not reach target tissues. I'm thinking if theres another way to activate TCF/LEF genes without β-catenin, that would be even better than using indirect growth factors.
All the research points to this theory, the AGA DPC inhibiting growth of keratinocytes but normal DPC promoting growth of HaCat. We already know its androgens, and we kind of knew that AR inhibited β-catenin somehow. I think this is the definitive answer, its the binding of AR to our precious β-catenin that causes AGA.
I remember making a post about tgf-beta and dug this up:
So TGF-beta can potentiate AR via autocrine loop? the f***, it just keeps getting worse
Androgen receptor transactivity is potentiated by TGF-b1 through Smad3 but checked by its coactivator Hic-5/ARA55 in balding dermal papilla cells
(was behind paywall but thats not going to stop me now)
Our data presented here suggest that TGF-b1 can enhance androgen sensitivity through Smad3 in the dermal papilla of AGA in an autocrine manner. Because TGF-b1 from bald DPCs inhibits hair follicle epithelial cell growth in a paracrine manner [1], TGFb1 exerts its pathogenic roles with dual secretion, autocrine and paracrine, between epithelium and dermal papilla in AGA. On the other hand, although Hic-5/ARA55 upregulates androgen sensitivity via coactivation for AR in DPCs [6], the data obtained in our current study indicated that this molecule impedes the AR stimulation by TGF-b1. This may be due to crosstalk between Hic-5/ARA55 and Smad3 [8] or possibly the attenuated effect of TGF-b1 on the high expression of Hic-5/ARA55, which is reportedly increased by TGF-b1 [9]. Given that Hic-5/ARA55 is highly expressed in the androgen-sensitive DPCs from AGA [6], a complex compensatory mechanism through reciprocal interaction must be in place between TGF-b-Smad and androgen-AR signaling pathways in the hair follicles of AGA.
So it looks like hic5/ARA55 is bad, but is keeping check on the additional AR effect of TGF-beta. A powerful or mild anti-oxidant is probably all we need to fix this part but I think we should both look into hic5/ara55 and other co-activators that could be making AGA worse over time.
Induction of transforming growth factor-beta 1 by androgen is mediated by reactive oxygen species in hair follicle dermal papilla cells
Another thing I just noticed is that rat DPC overexpressing AR has the same phenotype as AGA:
During sub-cultivation of DPCs, sensitivity to androgens may be low because of the reduced expression level of AR (11). AR has been detected in the DPCs of human skin (5), and the DPCs of bald frontal scalps express higher levels of AR than those of non-balding occipital scalps (4). Therefore, to confirm our hypothesis, we used rat DPCs that over-express AR.
We also know that DKK-1 is induced by reactive species, specifically JNK mediated. And looking back over the research it looks like the DPC themselves produce DKK-1:
DKK-1 messenger RNA is upregulated in 3-6 hours after 50-100 nM DHT treatment and ELISA showed that DKK-1 is secreted from DP cells in response to DHT.
http://www.ncbi.nlm.nih.gov/pubmed/17657240
http://www.ncbi.nlm.nih.gov/pubmed/17657240
So although there are quite a few similarities its not quite apples to apples which irritates me.
My current understanding:
Increasing β-catenin will saturate the AR in the presence of DHT/T and will not successfully activate TCF/LEF
However without DHT/T, β-catenin will be able to activate TCF/LEF which is good because we can just try to reduce AR. I'm unsure if AR antagonists will still bind β-catenin.
Increasing β-catenin to suraphysical levels could in theory bypass the AR recruitment
AR will increase ROS and subsequent TGF-β1 + DKK-1 via DPC regardless of β-catenin being present. This can be counteracted with an anti-oxidant
AR can increase GSK3β thereby reducing available β-catenin
Next post will be new treatments and an approach plan along with my current progress.
Leave a comment: